AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04636918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Ophthalmic
Description: Prospective interventional study (single arm)
Study NCT01122355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid modification
Description: 1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
Study NCT01193764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% cocoa powder
Description: A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
Study NCT00961415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500mg/m2 iv on day 1 of each 3-week cycle
Study NCT04664387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: A coronary angiography is a test to find out if there is stenosis in coronary artery.
Study NCT04144829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU
Description: Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
Study NCT04144829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin
Description: Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
Study NCT00556959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose clonidine HCl sustained release
Description: high dose clonidine HCl sustained release tablets for 8 weeks
Study NCT00556959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose clonidine HCl sustained release
Description: low dose clonidine HCl sustained release tablets for 8 weeks
Study NCT00556959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets for 8 weeks
Study NCT04619537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
Study NCT02495675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannulas
Description: Comparison of different flow levels
Study NCT02495675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional flow via nasal prongs
Description: Low flow of air delivered through conventional nasal prongs
Study NCT03361345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical tranexamic acid in cream form applied to dark spots on right side of face.
Study NCT03361345 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
Study NCT03510936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
Study NCT02990377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RL-supported IVR intervention
Description: Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
Study NCT01193764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: gelatin (Gelita)
Description: A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
Study NCT00144885 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Modification of therapy
Description: Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
Study NCT00719797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00719797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00719797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT04930939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training cardiac rehabilitation program
Description: Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
Study NCT03318718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia with non-depolarizing NMBA Rocuronium
Description: Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
Study NCT03318718 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurement
Description: TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
Study NCT03318718 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MEP measurement
Description: MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
Study NCT01277081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol hot drink
Description: Hot drink containing paracetamol
Study NCT01277081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol tablets
Description: Paracetamol tablets
Study NCT00420641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: GSK372475 1.0-1.5 mg/day
Study NCT00420641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine 20-30 mg/day
Study NCT00420641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo to Match
Study NCT04930939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training cardiac rehabilitation program
Description: Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
Study NCT04009083 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care MRI
Description: Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
Study NCT04009083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET scan added to MRI
Description: 18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
Study NCT03732924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement
Description: To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
Study NCT03732924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement
Description: To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
Study NCT02999503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Nutritional education trough a personal online nutritional consultant
Study NCT03736707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective HFOV
Description: Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
Study NCT01203488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
Study NCT03736707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMV
Description: CMV was delivered by time-cycled, pressure-limited ventilators
Study NCT01076127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketllebell training
Description: Kettlebell training 3 x 20 min a week for 8 weeks
Study NCT01076127 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Receives a health examination before and after the intervention period, and are advised to stay active.
Study NCT00048087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: 250 mg by mouth daily each day for 4 weeks.
Study NCT00048087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
Study NCT01203488 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Control infants received a sham procedure rather than placebo injections.
Study NCT02749890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02749890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02749890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: Oral
Study NCT02749890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: Oral
Study NCT00908778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: intravitreal injection
Study NCT03156140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion
Description: Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
Study NCT03459586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 9zest app facilitated exercise
Description: The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
Study NCT00585182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg once daily
Description: Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
Study NCT06397638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue carotid stenting
Description: Rescue carotid stenting in tandem occlusions
Study NCT03390153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi flexible socket
Description: The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
Study NCT03390153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rigid fiber socket
Description: The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
Study NCT01104766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT01104766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT01104766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study NCT04256499 — intervention group
Intervention type: PROCEDURE
Intervention: Acute water load test
Description: The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
Study NCT01251458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel
Description: Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
Study NCT01651884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix)
Description: Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
Study NCT01651884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (Neuroconn)
Study NCT01341470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously or subcutaneously
Study NCT01636037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (generic version of Sinemet)
Description: Oral levodopa 900mg daily as tolerated.
Study NCT01341470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intravenously or subcutaneously
Study NCT02909595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Description: Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
Study NCT02909595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basket catheter
Description: Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
Study NCT02558569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: L form of bupivacaine with less cardiotoxicity.
Study NCT02558569 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: NSS
Description: Clear intravenous fluid looks alike local anesthetic.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 10 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 30 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
Study NCT01818934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip ultrasound
Description: Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 100 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 300 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 1000 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 high or low dose (or placebo)
Description: Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 dose E1
Description: E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
Study NCT04452006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo will be provided in HPMC capsules for oral administration.
Study NCT03817346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GT-002
Description: Single ascending dose
Study NCT03817346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Comparator single ascending dose
Study NCT02120846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flywheel leg-press resistance exercise
Study NCT03179631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: 10, 20 mg/kg
Study NCT03179631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 10, 20 mg/kg
Study NCT00692055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 375 mg / esomeprazole 20 mg
Study NCT00692055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: naproxen 375 mg
Study NCT00919893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cernilton
Description: Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
Study NCT00919893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
Study NCT05484687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
Description: Administer 1.5 mg/kg lidocaine
Study NCT02782078 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Clindamycin and rifampicin dosages
Description: blood samples for clindamycin and rifampicin dosages (for each patient)